State Street SPDR S&P Biotech ETF (XBI)
State Street SPDR S&P Biotech ETF (XBI) — healthcare and biotech ETF. Analyze it on ETF Copilot.
U.S. biotech stocks, focused on innovation and development in the sector.
A focused bet on biotech innovation — higher risk, higher potential reward for a portfolio seeking growth beyond current earnings.
14% of XBI is its ten largest holdings.
Less concentrated than 98% of Healthcare & Biotech ETFs.
What's inside XBI: Size (large 12%, mid 39%, small 50%); Geography (international 5%, us 95%).
As of July 29, 2026, ETF Copilot scores State Street SPDR S&P Biotech ETF (XBI) 2.1 out of 10 overall.
Updated July 29, 2026
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 2.1 / 10
- Growth: 0.2 / 10
- Risk: 1.4 / 10
- Profitability: 2.1 / 10
- Return: 4.5 / 10
Register free to unlock XBI's price, fees, yield, and holdings on ETF Copilot.
Register free →